Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 41 public companies in the “Industrial organic chemicals” industry, but how does it contrast to its competitors? We will compare Cyclo Therapeutics to similar businesses based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, valuation, risk and earnings.
Risk and Volatility
Cyclo Therapeutics has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics’ competitors have a beta of -129.53, indicating that their average share price is 13,053% less volatile than the S&P 500.
5.2% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 49.9% of shares of all “Industrial organic chemicals” companies are held by institutional investors. 12.3% of Cyclo Therapeutics shares are held by insiders. Comparatively, 11.6% of shares of all “Industrial organic chemicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Cyclo Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cyclo Therapeutics Competitors||-435.63%||-59.61%||-0.06%|
This is a summary of current recommendations for Cyclo Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cyclo Therapeutics Competitors||272||1015||1294||40||2.42|
Cyclo Therapeutics presently has a consensus target price of $16.00, indicating a potential upside of 479.71%. As a group, “Industrial organic chemicals” companies have a potential upside of 20.38%. Given Cyclo Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Cyclo Therapeutics is more favorable than its competitors.
Earnings and Valuation
This table compares Cyclo Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cyclo Therapeutics||$1.59 million||-$14.29 million||-1.22|
|Cyclo Therapeutics Competitors||$4.57 billion||$425.65 million||6.65|
Cyclo Therapeutics’ competitors have higher revenue and earnings than Cyclo Therapeutics. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Cyclo Therapeutics competitors beat Cyclo Therapeutics on 8 of the 13 factors compared.
About Cyclo Therapeutics (Get Rating)
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.